Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: A systematic review with meta-analysis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Zhang, Zhixuan ^a   Wang, Ting ^a   Zhang, Jun ^a   Cai, Xiaohong ^a   Pan, Changchuan ^a   Long, Yu ^a   Chen, Jing ^a   Zhou, Chengya ^a   Yin, Xude ^a  

^a SICHUAN CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ASIAN; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CAUCASIAN; DISEASE FREE SURVIVAL; EGFR GENE; ETHNIC DIFFERENCE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MUTATION RATE; OVERALL SURVIVAL; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; META ANALYSIS; MORTALITY; MUTATION; PROGNOSIS; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84923290460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106053     Document Type: Review

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
2. Lauro S, Onesti CE, Righini R, Marchetti P (2014) The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res 34: 1537-1545.
3. Chen F, Cole P, Bina WF (2007) Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 16: 2724-2729. (Pubitemid 351210549)
4. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, et al. (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139. (Pubitemid 40188446)
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
6. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719. (Pubitemid 33040631)
7. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, et al. (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221-1230.
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
9. Lee KH, Min HS, Han SW, Oh DY, Lee SH, et al. (2008) ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60: 401-407. (Pubitemid 351726353)
10. Na II, Rho JK, Choi YJ, Kim CH, Park JH, et al. (2007) The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer 57: 96-102. (Pubitemid 46843338)
11. Lee JG, Kim S, Shim HS (2012) Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer 77: 156-161.
12. Koh Y, Jang B, Han SW, Kim TM, Oh DY, et al. (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5: 320-325.
13. Na II, Rho JK, Choi YJ, Kim CH, Koh JS, et al. (2007) Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J Korean Med Sci 22: 393-399.
14. Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, et al. (2014) Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer 83: 389-395.
15. Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, et al. (2007) Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. J Clin Oncol 25: 3952-3957. (Pubitemid 47477273)
16. Sonobe M, Nakagawa M, Takenaka K, Katakura H, Adachi M, et al. (2007) Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 95: 63-69. (Pubitemid 46122720)
17. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, et al. (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3: 111-116. (Pubitemid 351323183)
18. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, et al. (2008) Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung. J Thorac Oncol 3: 704-710.
19. Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, et al. (2009) Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer 64: 295-300.
20. Galleges Ruiz MI, Floor K, Steinberg SM, Grünberg K, Thunnissen FB, et al. (2009) Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 100: 145-152.
21. Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, et al. (2009) Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer 66: 107-113.
22. Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, et al. (2009) Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol 135: 1647-1654.
23. D'Angelo SP, Janjigian YY, Kris MG, Pao W, Riely GJ, et al. (2010) Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. J Clin Oncol 28(Suppl): 7011.
24. Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, et al. (2010) Prognostic Implications of Epidermal Growth Factor Receptor and KRAS Gene Mutations and Epidermal Growth Factor Receptor Gene Copy Numbers in Patients with Surgically Resectable Non-small Cell Lung Cancer in Taiwan. J Thorac Oncol 5: 1175-1184.
25. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, et al. (2011) Prognostic and Predictive value of EGFR Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. J Thorac Oncol 6: 139-147.
26. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, et al. (2013) The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg 96: 962-968.
27. Sun HB, Ou W, Li Y, Fang Q, Qin J, et al. (2013) Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer. Clin Lung Cancer 14: 376-382.
28. Ragusa, M., Vannucci, J. , Ludovini, V., Bianconi, F., Treggiari, S., Tofanetti, F.R., Flacco, A., Colella, R., Sidoni, A., Crinò, L., Puma, F. "Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients" in American Journal of Clinical Oncology: Cancer Clinical Trials,Volume 37, Issue 4, August 2014, Pages 343-349
29. Dong Y, Li Y, Peng H, Jin B, Huang A, et al. (2013) Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas. Zhongguo Fei Ai Za Zhi 16: 177-183.
30. Maki Y, Soh J, Ichimura K, Shien K, Furukawa M, et al. (2013) Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncol Rep 29: 133-140.
31. Ohba T, Toyokawa G, Kometani T, Nosaki K, Hirai F, et al. (2014) The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surg Today 44: 478-486.
32. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC, et al. (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer: In press.
33. Liu WS, Zhao LJ, Pang QS, Yuan ZY, Li B, et al. (2014) Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol 31: 771.
34. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559.
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
36. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-500. (Pubitemid 38720929)
37. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909.
38. Shepherd FA, Tsao MS (2006) Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24: 1219-1220. (Pubitemid 46638822)
39. Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, et al. (2013) The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 8: 171-178.
40. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al. (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865. (Pubitemid 46224186)
41. Sugio K, Uramoto H, Onitsuka T, Mizukami M, Ichiki Y, et al. (2009) Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 64: 314-318.